WEY Wolfeye Resource Corp

LexaGene Provides a Corporate Update

LexaGene Provides a Corporate Update
EN
05/10/2020

Underlying

WEYWolfeye Resource Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wolfeye Resource Corp

 PRESS RELEASE
Free
WEY Wolfeye Resourc...

LexaGene Files for Chapter 7 Bankruptcy

LexaGene Files for Chapter 7 Bankruptcy BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics Diagnostics, Inc., filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code. The filing, which took place earlier today at the U.S. Bankruptcy Court for the District of Massachusetts, located in Boston, Massachusetts, will result in federal ...

February 24, 2023 1 EN
 PRESS RELEASE
Free
WEY Wolfeye Resourc...

LexaGene Provides Update on BioPharma Sector

LexaGene Provides Update on BioPharma Sector BEVERLY, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to provide the following update on the Company’s efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics. Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a l...

February 8, 2023 1 EN
 PRESS RELEASE
Free
WEY Wolfeye Resourc...

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing ...

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers BEVERLY, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to announce exciting news regarding the ability of the MiQLab System to detect Mycoplasma at minute levels. Dr. Jack Regan, CEO and Founder of LexaGene commented, “In the process of completing the follow-on feasibility study with one of our biopharma customers, I’m thrilled...

January 18, 2023 1 EN
 PRESS RELEASE
Free
WEY Wolfeye Resourc...

BioPharma Engages LexaGene in Second Feasibility Study

BioPharma Engages LexaGene in Second Feasibility Study Cancels Plans to Reprice Meridian’s Warrants BEVERLY, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to announce the large biopharma company (>$100B Market Cap) that previously purchased a MiQLab System has engaged LexaGene in a second statement of work (“SOW”) that builds off of the previously completed SOW. Dr. Jack Regan, LexaGene’s CEO and Founder commented, “In the biopharma indu...

December 16, 2022 1 EN
 PRESS RELEASE
Free
WEY Wolfeye Resourc...

LexaGene Holdings Proposes to Amend Warrants Terms

LexaGene Holdings Proposes to Amend Warrants Terms BEVERLY, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on February 7 and February 18, 2022 to Meridian LGH Holdings, LLC and expiry five years after the date of issue. An aggregate of 18,500,000 Warrants were initially issued with an exercise price of CAD$0.45 per common s...

December 7, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch